EP1411061A1 - Peptides mimetiques de l'acide poly-alpha 2,8-sialique et leurs applications - Google Patents

Peptides mimetiques de l'acide poly-alpha 2,8-sialique et leurs applications Download PDF

Info

Publication number
EP1411061A1
EP1411061A1 EP20020292548 EP02292548A EP1411061A1 EP 1411061 A1 EP1411061 A1 EP 1411061A1 EP 20020292548 EP20020292548 EP 20020292548 EP 02292548 A EP02292548 A EP 02292548A EP 1411061 A1 EP1411061 A1 EP 1411061A1
Authority
EP
European Patent Office
Prior art keywords
peptide
seq
psa
peptides
phage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20020292548
Other languages
German (de)
English (en)
Inventor
designation of the inventor has not yet been filed The
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Hamburg
Schafer-N
Aix Marseille Universite
Centre National de la Recherche Scientifique CNRS
Original Assignee
Universitaet Hamburg
Schafer-N
Centre National de la Recherche Scientifique CNRS
Universite de la Mediterranee Aix Marseille II
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Hamburg, Schafer-N, Centre National de la Recherche Scientifique CNRS, Universite de la Mediterranee Aix Marseille II filed Critical Universitaet Hamburg
Priority to EP20020292548 priority Critical patent/EP1411061A1/fr
Priority to ES03769800T priority patent/ES2359810T3/es
Priority to DE60335278T priority patent/DE60335278D1/de
Priority to DK03769800.8T priority patent/DK1551867T3/da
Priority to EP03769800A priority patent/EP1551867B1/fr
Priority to JP2004544626A priority patent/JP2006516186A/ja
Priority to EP10011987A priority patent/EP2295568A3/fr
Priority to AU2003278501A priority patent/AU2003278501A1/en
Priority to AT03769800T priority patent/ATE490973T1/de
Priority to CA002501994A priority patent/CA2501994A1/fr
Priority to US10/531,701 priority patent/US7417025B2/en
Priority to PT03769800T priority patent/PT1551867E/pt
Priority to PCT/IB2003/005108 priority patent/WO2004035609A2/fr
Publication of EP1411061A1 publication Critical patent/EP1411061A1/fr
Priority to US12/176,008 priority patent/US8048858B2/en
Priority to JP2010178921A priority patent/JP2011016810A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Definitions

  • the invention relates to poly- ⁇ 2,8-sialic acid (PSA) mimetic peptides able to modulate specifically PSA-dependent NCAM functions in vitro and in vivo , to pharmaceutical composition comprising the same and to their use for the treatment of neurodegenerative diseases, brain and spine lesions, age-related learning and memory problems, and cancer.
  • PSA poly- ⁇ 2,8-sialic acid
  • NCAM neural cell adhesion molecule
  • PSA poly- ⁇ 2,8-sialic
  • PSA is composed of negatively charged N-acetylneuraminic acid (sialic acid) residues in an alpha 2,8 linkage.
  • Single PSA chain may consist of more than 50 monomers, but the chain length may vary substantially in NCAM isolated from various sources (Rougon et al., Eur. J. Cell. Biol., 1993a, 61, 197-207).
  • Studies using NMR microscopy indicate that PSA has a helical structure in solution consisting of eight or more contiguous sialic acid units (Rougon et al., 1993a, precited; Yamasaki et al. 1991).
  • PSA has a large hydrated volume and high negative charge density, and therefore is well placed to attenuate adhesion forces and to negatively regulate overall cell surface interactions (Rutishauser et al., Science, 1988, 240, 53-57).
  • NCAM knock-out mice suggesting that NCAM is the major if not the only carrier of PSA in vertebrate brain.
  • NCAM with high PSA content is associated with morphogenetic changes during development such as cell migration, synaptogenesis and axonal growth and branching, while in adult brain poorly sialylated forms of NCAM are dominating (Rougon et al., Polysialic Acid, 1993b, Roth J.R., Rutishauser U. and Troy F. A. (eds), Birkhauser-Verlag: Basel, 323-333; Rutishauser et al, 1998, precited; Edelman et al., Annu. Rev. Cell. Biol., 1986, 2, 81-116).
  • PSA-NCAM does persist in adult brain structures that display a high degree of plasticity (Rougon et al., 1993a, precited).
  • PSA-NCAM is required for two essential forms of activity-induced synaptic plasticity, long-term potentiation (LTP) and long-term depression (LTD), that are believed to be central to learning and memory as well as activity-dependent pattern formation during development.
  • LTP long-term potentiation
  • LTD long-term depression
  • PSA-NCAM is re-expressed in several pathological situations such as muscle regeneration (Figarella-Branger et al., Cancer Res., 1990, 50, 6364-6370) or brain neurodegenerative diseases (Le Gal La Salle et al., J. Neurosci., 1992, 12, 872-882). Based on these observations, PSA-NCAM emerged as an important permissive factor for dynamic changes in cell surface interactions required for morphogenesis and tissue remodelling (Rougon et al., 1993b, precited; Figarella-Branger, 1993; Rutishauser, Development, 1992, 99-104).
  • PSA-NCAM Many tumors with neural and endocrine characteristics expressed PSA-NCAM.
  • PSA-NCAM had been detected in neuroblastomas and medulloblastomas (Figarella-Branger et al., precited), small cell carcinoma of the lung (Patel et al., Int. J. Cancer, 1989, 44, 573-578) and rhabdomyosarcomas, and is possibly related to the invasive and metastatic potential of these tumors (Rougon et al., 1993b, precited).
  • injection of neuraminidase into a nude mouse model for metastasis showed that removal of PSA on the primary tumor delayed metastasis. (Daniel et al, Oncogene, 2001, 20, 997-1004).
  • the molecule PSA-NCAM and more precisely the carbohydrate PSA represents one of the potential targets of future therapeutic approaches to promote plasticity and functional recovery after brain damage or to prevent metastasis formation.
  • the inventors have isolated peptides which are molecular mimetics of a PSA epitope and they have demonstrated that these PSA mimetic peptides are able to modulate (enhance or inhibit), in vivo , in a PSA-dependent manner, cellular processes that are normally affected by polysialylation of NCAM.
  • the inventors have demonstrated a significant effect of the PSA mimetic peptides, in vivo, on axons growth, guidance and fasciculation as well as on neurons migration.
  • PSA mimetic peptides which are active in vivo at low doses ( ⁇ M concentration) and do not exhibit any cytotoxicity are useful for:
  • the PSA mimetic peptides are useful as complementary tools to uncover mechanisms of action and unknown functions of the carbohydrate PSA.
  • the present invention relates to a peptide, characterized in that it comprises a B epitope recognized by an anti-poly- ⁇ 2,8 sialic acid (PSA) antibody.
  • PSA anti-poly- ⁇ 2,8 sialic acid
  • the "B epitope recognized by an anti- PSA antibody” refers to a peptide which reacts specifically and selectively, in vitro and in vivo , with the paratope of an antibody produced by lymphoid cells in response to a stimulation with poly- ⁇ 2,8 sialic acid as an immunogen.
  • Anti-PSA antibodies prepared by standard techniques, following protocols as described for example in Antibodies : A Laboratory Manual, E. Howell and D Lane, Cold Spring Harbor Laboratory, 1988 are well-known in the art; they include, without limitation, monoclonal antibodies 735 (Frosch et al., P.N.A.S;1985, 82, 1194-1198), 30H12 (Coquillat et al., Infect. Immun., 2001, 69, 7130-7139) or MenB (ABCYS AbC0019).
  • the peptide comprising or consisting of a B epitope as defined above presents a sequence consisting of 5 to 30 amino acid residues, preferably 9 to 15, most preferably about 12 amino acid residues.
  • the invention includes linear and cyclic peptides.
  • Preferred cyclic peptides according to the invention comprise peptides in which the side chain of one amino acid in the peptide chain is attached covalently to the side chain of another amino acid in the peptide chain via formation of a covalent bond, such as a disulfide bond between two cysteine residues.
  • peptides according to the invention refer to peptides which have the following activities:
  • the peptides according to the invention are denominated hereafter PSA mimetic peptides, mimetic peptides or peptides.
  • the mimetic peptides antibody-binding activity is verified by standard immunoassay which are well-known by a person skilled in the art; for example, 100 % peptide binding is observed at concentrations of 10 -4 M and above in an ELISA with an anti-PSA monoclonal antibody at the concentration of 2,5 ⁇ g/well, and this antibody binding activity is specifically inhibited by a PSA analog such as colominic acid.
  • the mimetic peptides biological activity is verified by standard cell growth and cell migration assays in vitro or in vivo , which are well-known by a person skilled in the art; for example, assays on primary neurons from different sources (dorsal root ganglion, cerebellar neurons, retina, %) show the following effects:
  • the mimetic peptide biological activity is specifically inhibited by enzymatic digestion with endoneuraminidase and is absent in NCAM knock-out mice.
  • said peptide comprises a sequence which is selected from the group consisting of the sequences SEQ ID NO: 1 to 26, corresponding respectively to DSPLVPFIDFHP, LWQPPLIPGIDF, QIEPWFTPEDFP, TRLAPLVFPLDY, SWLQMPWALVRT, EIHLRMIKQITI, WHLEYMWRWPRL, LIEQRLPKHILT, YETSSSRLLAYA, TLASQLSNTSAY, SDQGVNGSWSNP, WHNWNLWAPASPT, WHWQWTPWSIQP, IKSPLTWLVPPD, SHLDLSTGHRTS, CYPLNPEVYHCG, CWPLSHSVIVCG, CSSVTAWTTGCG, CYMASGVFLCG, CWPLGPSTYICG, CSLIASMETGCG, CSKIASMETGCG, CYIGDPPFNPCG, CWPLGDSTVICG CPLRLAFTFGCG and CTRMSHGYWICG
  • the invention also includes any functional derivative of the peptides as defined above, comprising one or more modifications which do not affect substantially the antibody binding and biological activities of the initial peptide.
  • Such modifications include for example: addition and/or deletion and/or substitution of one or more amino acid residue in the peptide chain, and/or replacement of one or more of the amide bond by a non-amide bond, and/or replacement of one or more amino acid side chain by a different chemical moiety, and/or protection of the N-terminus, the C-terminus, or one or more of the side chain by a protecting group, and/or introduction of double bonds and/or cyclization and/or stereospecificity into the amino acid chain to increase rigidity, and/or binding affinity and/or enhance resistance to enzymatic degradation of the peptides. Since all the variations are known in the art, it is submitted that a person skilled in the art will be able to produce, test, identify and select other peptides/epitopes according to the present invention.
  • “Equivalent amino acid” is used herein to name any amino acid that may substitutes for one of the amino acids belonging to the initial peptide structure without modifying the antibody binding and biological activities of the initial peptide structure.
  • These equivalent amino acids may be determined by their structural homology with the initial amino acids to be replaced and by their biological activity on the target cells of the peptides according to the invention.
  • substitutions like, for example, leucine by valine or isoleucine, aspartic acid by glutamic acid, glutamine by asparagine, asparagine by lysine etc., it being understood that the reverse substitutions are permitted in the same conditions.
  • said peptide consists of a sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 26.
  • said peptide is selected from the group consisting o f:
  • said peptide is associated with another peptide or non-peptide molecule and/or incorporated into a suitable support including for example, polymers, lipidic vesicles, microspheres, proteins and the like.
  • association which may improve the peptide solubility, absorption, bioavailability, biological half life, is formed, by using techniques well known in the art; it may be through, without limitation, covalent bonding (e.g., amide bond, disulfide bond%), or through chelation, electrostatic interactions, hydrophobic interactions, hydrogen bonding, ion-dipole interactions, dipole-dipole interactions, or any combination of the above.
  • covalent bonding e.g., amide bond, disulfide bond
  • electrostatic interactions e.g., electrostatic interactions, hydrophobic interactions, hydrogen bonding, ion-dipole interactions, dipole-dipole interactions, or any combination of the above.
  • said peptide is incorporated in a complex comprising a plurality of identical or different peptides according to the invention, linked by covalent or non-covalent bonds.
  • said peptide is associated with a marker such as a fluorescent marker, to facilitate the detection of the peptides according to the invention.
  • said peptide is included in a fusion protein to allow expression of said peptide.
  • the peptide of the present invention may be prepared by any suitable process. Preferably, it is obtained by chemical synthesis in liquid or solid phase by successive couplings of the different amino acid residues to be incorporated (from the N-terminal end to the C-terminal end in liquid phase, or from the C-terminal end to the N-terminal end in solid phase) wherein the N-terminal ends and the reactive side chains are previously blocked by conventional groups.
  • solid phase synthesis the technique described by Merrifield (J. Am. Chem. Soc., 1964, 85, 2149-2154) may be used.
  • the peptide of the present invention may also be obtained by genetic engineering technology.
  • a typical example comprise culturing a host cell containing an expression vector comprising a nucleic acid sequence encoding said peptide, under conditions suitable for the expression of the peptide, and recovering the peptide from the host cell culture.
  • the peptide may be included in a fusion protein by cloning a cDNA into an expression vector in frame with a polynucleotide coding for the peptide of the invention.
  • multimer of identical or different peptides can also be produced by expressing a polynucleotide coding for multiple copies of a monomer, or coding for different monomers.
  • the invention also provides a polynucleotide encoding the peptide according to the invention, as well as the complement of said polynucleotide, and fragments of at least 5 nucleotides thereof.
  • the invention provides the nucleotide sequences encoding the peptides SEQ ID NO: 1 to SEQ ID NO: 26, including all possible examples of nucleotide sequences encoding these peptides which result from the degeneration of the genetic code.
  • Nucleic acids of the invention may be obtained by the well-known methods of recombinant DNA technology and/or chemical DNA synthesis.
  • the invention also provides recombinant vectors comprising a polynucleotide encoding the peptide of the invention.
  • Vectors of the invention are preferably expression vectors, wherein a sequence encoding a peptide of the invention is placed under control of appropriate transcriptional and translational control elements. These vectors may be obtained and introduced in a host cell by the well-known recombinant DNA and genetic engineering techniques.
  • the invention also comprises a prokaryotic or eukaryotic host cell transformed by a vector of the invention, preferably an expression vector.
  • the invention further concerns a pharmaceutical composition
  • a pharmaceutical composition comprising an effective amount of the peptide of the invention, optionally in a combination with a pharmaceutically acceptable carrier.
  • the optional carriers of the pharmaceutical compositions of the invention can be any vehicle for parenteral, oral, aerosol, nasal or ocular administration of drugs acting on the nervous system.
  • a composition according to the invention is administered through the nose, which enables the penetration of the aerosol composition to the Central Nervous System through the olfactory nerve or via the ocular route or by any other suitable method of administration as described in W.M. Pardridge, Peptide drug Delivery, Raven Press, N. Y., 1991.
  • the invention further concerns the use of a peptide of the invention for the preparation of a medicament for the prevention and/or the treatment of a pathological condition selected from the group consisting of: neurodegenerative diseases, brain and spine lesions, age-related learning and memory problems and cancer.
  • the amount of peptide in the composition is in a concentration ranges from about 0.1 ⁇ M to about 10 ⁇ M.
  • the preferred frequency of administration and effective dosage will vary from one subject to another.
  • EXAMPLE 1 PEPTIDE LIBRARY SCREENING WITH ANTI-PSA MONOCLONAL ANTIBODY
  • PEG/NaCl solution was added to the supernatant (1 volume PEG/NaCl for 6 volumes supernatant) and phage was precipitated overnight at 4 °C.
  • the solution containing the precipitate was centrifuged for 15 min at 10,000 rpm at 4 °C.
  • the supernatant was decanted and the pellet was suspended in 1 ml TBS and re-precipitated with 1/6 volume of PEG/NaCl for 1 h on ice. After centrifugation, the pellet was finally suspended in 200 ml TBS, 0.02 % NaN 3 .
  • This amplified eluate was dissolved in TBST and a second and a third round of biopanning were carried out as described above; for the second round, the TBST used for washing and phage incubation contained 0.1 % Tween 20; in the third round the content was 0.5 %.
  • the non-amplified eluate from the third round was subsequently tittered on LB/IPTG/X-gal plates. Blue plaques were picked and the phage clone amplified in 2 ml E. coli ER2537 culture for 4.5 h at 37 °C, with vigorous shaking. After centrifugation for 10 min at 10,000 rpm, at 4 °C, the supernatant was mixed with 1/6 volume PEG/NaCl and the phage precipitated at 4 °C overnight. The precipitate was centrifuged for 15 min at 10,000 rpm at 4 °C. The pellet was suspended in 100 ⁇ l TBS.
  • MaxiSorpTM plate wells were coated with 100 ⁇ l mAb solution (25 ⁇ g/ml) for 2 h at room temperature. The control wells were coated only with the blocking solution. In parallel, the phage dilution plates were blocked with 200 ⁇ l blocking solution for 2 h. The antibody coated wells and the control wells of the ELISA plates were blocked with 200 ⁇ l blocking solution for 1 h. In parallel the phage dilution plates were washed 6 times with TBST and 120 ⁇ l TBST was added to the wells. An appropriate volume of a phage solution was added to the first well and the volume was adjusted to 140 ⁇ l with TBST.
  • the phage solution in well one was diluted in the ratio 1/7 by taking 20 ⁇ l out of the first well and transferring into the second, also to achieving the total volume of 140 ⁇ l. This was repeated for the remaining wells.
  • the phage dilutions for the control wells were done the in same way.
  • the blocked ELISA plate was washed 6 times with TBST and the phage dilutions or the competitor solution were added. After incubation for 1 h, the plates were washed 10 times with TBST. After incubation for 1 h, the wells were washed 10 times with TBST. 100 ⁇ l of the HRP-conjugated M13 antibody solution was added to the wells.
  • the wells were washed 10 times with TBST and 100 ⁇ l of the HRP substrate solution (with H 2 O 2 ) was added to the wells.
  • the plates were read at 405 nm using a microplate reader.
  • the phage presenting sequence SEQ ID NO: 1 (DSPLVPFIDFHP) showed the best binding to mAb 735 in comparison with the other phages. This binding was competed with colominic acid, whereas dextran showed no competition effects.
  • the phage presenting sequence SEQ ID NO: 4 showed similar values. Because of the low occurrence of sequence SEQ ID NO: 4 it was decided to synthesize sequence SEQ ID NO: 1 (peptide p21) and a randomized variant of sequence SEQ ID NO: 1 (peptide p22: PDHIFVFSPDLP, SEQ ID NO: 28) as control.
  • This peptide solution was added to the pooled fractions containing maleimide-activated /biotinylated BSA. After 2 h incubation at room temperature, 100 ml cysteine solution was added to block the non-reacted maleimide groups. After 1 h, the reaction solution was dialysed 5 times with 1 ml PBS, in an ultrafiltration unit. The biotinylated conjugate was dissolved in PBS and aliquots stored at - 20 °C.
  • the peptide-BSA conjugate in well one was diluted in the ratio 1/7 by taking 20 ⁇ l out of the first well and transferring into the second also to achieve the total volume of 140 ⁇ l. This was repeated for the remaining wells.
  • the peptide-BSA conjugate dilutions for the control wells were done the same way.
  • the blocked ELISA plates were washed 6 times with TBST and the peptide-BSA conjugate dilutions or 100 ⁇ l of the mixed competitor solution was added to the wells. After incubation for 1 h, the wells were washed 10 times with TBST and 100 ⁇ l of the alkaline phosphatase substrate solution was added to the wells. The plates were read out after 10 to 60 min using a microplate reader at 405 nm.
  • Table X shows a clear inhibition of p21 binding in the presence of colominic acid.
  • chondroitin sulfate C had no influence on the binding of peptide B.
  • Table XI shows no binding to mAb 735 for the randomized variant of p21 conjugate (p22); no differences were observed when colominic acid or chondroitic sulfate C were present.
  • GFP transgenic mice have been previously described in Hadjantonakis et al. (Biotechnol., 2002, 2, 11-), and all analysis was performed on Swiss background.
  • NCAM knock out mice (NCAM -/-) have been previously described in Cremer et al., precited.
  • E13,5 DRGs were dissected out from mice embryos in HBSS medium and seeded on glass coverslips coated with polylysine or with peptides linked to BSA. Explants were cultured in the presence or the absence of the peptides under soluble form (40 ⁇ M) in two ml of neurobasal medium (DMEM/Ham's F12, 3 : 1 (V/V), GIBCO, buffered with 20mM Hepes), supplemented as described in Faivre-Sarrailh et al., J.Cell. Sci., 1999, 18, 3015-3027 and Chazal et al., J.Neurosci., 2000, 20, 1446-1457.
  • DMEM/Ham's F12, 3 : 1 (V/V) neurobasal medium
  • GIBCO buffered with 20mM Hepes
  • SVZ explants were performed as described in Chazal et al., precited. Briefly, 1-day-old mice were killed by rapid decapitation. Brains were dissected out and sectionned by Vibratome (Leica). The SVZ from the lateral wall of the anterior lateral ventricle horn was dissected out in HBSS medium (LIFE TECHNOLOGIES) and cut into 200-300 ⁇ m diameter explants. The explants were mixed with Matrigel (BECKTON DICKINSON) and cultured in four-well dishes.
  • HBSS medium LIFE TECHNOLOGIES
  • the gel was overlaid with 400 ⁇ l of serum-free medium containing B-27 supplement (LIFE TECHNOLOGIES), in the presence or the absence of 40 ⁇ M of peptides (p65, p66, reverse p65, p21 or p22) and 70 U of Endo N per milliliter.
  • mice SVZ 100 ⁇ m diameter explants of 1-day-old GFP mice SVZ were incubated fifteen minutes in DMEM supplemented with 10% fetal bovine serum in presence of 0.01 M of p65 or reverse peptide and stereotaxically grafted (0,5 ⁇ l) into six weeks old mice SVZ as described in Lois and Alvarez-Buylla (Science, 1994, 264, 1145-1148). Three or four days after the graft, animals were perfused intracardiacally with a 4% paraformaldehyde solution in PBS. Brains were dissected out, postfixed, cryoprotected, and freezed in isopentane.
  • Injections were performed as described in Monnier et al. (Developmental Biology, 2001, 229, 1-14). Briefly, a 2 X 2 cm window was cut into the shell over E3 chick embryos. One ⁇ l of Fast green with 10 mM of p65 or reverse peptide was injected into the right eye vitreous body using a capillary. After a five-days incubation at 37°C, (E8) retinae were dissected, spread onto nitrocellulose filters (MILLIPORE), and fixed with 4% paraformaldehyde solution in PBS.
  • MILLIPORE nitrocellulose filters
  • Mouse dorsal root ganglion explants (E13,5) were cultured in the presence of p65 and p66 cyclic mimetic peptides, either in soluble form or coated on the microplates as BSA conjugates. Cells cultured in the absence of peptides or in the presence of reverse peptides (coated or in soluble form) were used as controls.
  • p65 and p66 in a soluble form, induce a clear defasciculation of axon bundles (C versus A and F versus D ) and a significant increase in axonal growth (C versus A ) by comparison with the controls.
  • p65 and p66 in a coated form, induced an opposite effect on fasciculation (B versus A and E versus D) and no effect on neurite outgrowth.
  • p21 induces a significant decrease in the rate of migration of the neuronal precursors, compared to the corresponding control peptide (p22 peptide) ; the decrease is comparable to that observed in the endo N treated cells.
  • Figure 8 show that the presence of p65 peptide increases significantly the number of GFP positive cells migrating to the olfactory bulb (via the Rostral Migration Stream or RMS), by comparison with the control. This effect was observed as early as 3 days post-engraftment (figure 8E). These results were confirmed by the quantitative analysis showing that the number of GFP positive cells present in the olfactory bulb 3 days after the graft is increased 17 times in the presence of p65, by comparison with the control (figure 8G).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP20020292548 2002-10-16 2002-10-16 Peptides mimetiques de l'acide poly-alpha 2,8-sialique et leurs applications Withdrawn EP1411061A1 (fr)

Priority Applications (15)

Application Number Priority Date Filing Date Title
EP20020292548 EP1411061A1 (fr) 2002-10-16 2002-10-16 Peptides mimetiques de l'acide poly-alpha 2,8-sialique et leurs applications
AU2003278501A AU2003278501A1 (en) 2002-10-16 2003-10-16 Use of poly-alpha2,8-sialic acid mimetic peptides to modulate ncam functions.
AT03769800T ATE490973T1 (de) 2002-10-16 2003-10-16 Verwendung von poly-alpha-2,8-sialinsäure mimetischen peptiden zur modulierung von ncam funktionen
DK03769800.8T DK1551867T3 (da) 2002-10-16 2003-10-16 Anvendelse af poly-alfa-2,8-sialsyre-mimetiske peptider til modulering af NCAM-funktioner
EP03769800A EP1551867B1 (fr) 2002-10-16 2003-10-16 Utilisation de peptides mimetiques de l'acide poly-alpha-2,8-sialique pour moduler les fonctions des molecules d'adherence cellulaire neuronale
JP2004544626A JP2006516186A (ja) 2002-10-16 2003-10-16 ＮＣＡＭ機能を調節するためのポリ−α２，８−シアル酸模倣ペプチドの使用
EP10011987A EP2295568A3 (fr) 2002-10-16 2003-10-16 Peptides mimetiques de l'acide poly-alpha 2,8-sialique et leurs applications
ES03769800T ES2359810T3 (es) 2002-10-16 2003-10-16 Uso de péptidos miméticos del ácido poli-alfa 2,8-siálico para modular funciones de ncam.
DE60335278T DE60335278D1 (de) 2002-10-16 2003-10-16 Hen peptiden zur modulierung von ncam funktionen
CA002501994A CA2501994A1 (fr) 2002-10-16 2003-10-16 Utilisation de peptides mimetiques de l'acide poly-alpha2,8-sialique pour moduler les fonctions des molecules d'adherence cellulaire neuronale
US10/531,701 US7417025B2 (en) 2002-10-16 2003-10-16 Use of poly-α2,8-sialic acid mimetic peptides to modulate NCAM functions
PT03769800T PT1551867E (pt) 2002-10-16 2003-10-16 Utilização de péptidos miméticos do ácido polialfa- 2,8-siálico para regular funções de macn
PCT/IB2003/005108 WO2004035609A2 (fr) 2002-10-16 2003-10-16 Utilisation de peptides mimetiques de l'acide poly-$g(a)2,8-sialique pour moduler les fonctions des molecules d'adherence cellulaire neuronale
US12/176,008 US8048858B2 (en) 2002-10-16 2008-07-18 Use of poly-α2,8-sialic acid mimetic peptides to modulate NCAM functions
JP2010178921A JP2011016810A (ja) 2002-10-16 2010-08-09 ＮＣＡＭ機能を調節するためのポリ−α２，８−シアル酸模倣ペプチドの使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20020292548 EP1411061A1 (fr) 2002-10-16 2002-10-16 Peptides mimetiques de l'acide poly-alpha 2,8-sialique et leurs applications

Publications (1)

Publication Number Publication Date
EP1411061A1 true EP1411061A1 (fr) 2004-04-21

Family

ID=32039233

Family Applications (3)

Application Number Title Priority Date Filing Date
EP20020292548 Withdrawn EP1411061A1 (fr) 2002-10-16 2002-10-16 Peptides mimetiques de l'acide poly-alpha 2,8-sialique et leurs applications
EP10011987A Withdrawn EP2295568A3 (fr) 2002-10-16 2003-10-16 Peptides mimetiques de l'acide poly-alpha 2,8-sialique et leurs applications
EP03769800A Expired - Lifetime EP1551867B1 (fr) 2002-10-16 2003-10-16 Utilisation de peptides mimetiques de l'acide poly-alpha-2,8-sialique pour moduler les fonctions des molecules d'adherence cellulaire neuronale

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP10011987A Withdrawn EP2295568A3 (fr) 2002-10-16 2003-10-16 Peptides mimetiques de l'acide poly-alpha 2,8-sialique et leurs applications
EP03769800A Expired - Lifetime EP1551867B1 (fr) 2002-10-16 2003-10-16 Utilisation de peptides mimetiques de l'acide poly-alpha-2,8-sialique pour moduler les fonctions des molecules d'adherence cellulaire neuronale

Country Status (11)

Country Link
US (2) US7417025B2 (fr)
EP (3) EP1411061A1 (fr)
JP (2) JP2006516186A (fr)
AT (1) ATE490973T1 (fr)
AU (1) AU2003278501A1 (fr)
CA (1) CA2501994A1 (fr)
DE (1) DE60335278D1 (fr)
DK (1) DK1551867T3 (fr)
ES (1) ES2359810T3 (fr)
PT (1) PT1551867E (fr)
WO (1) WO2004035609A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103940985A (zh) * 2014-04-10 2014-07-23 首都医科大学 研究脑内源性神经干细胞迁移、增殖、分化的方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1411061A1 (fr) * 2002-10-16 2004-04-21 Centre National De La Recherche Scientifique (Cnrs) Peptides mimetiques de l'acide poly-alpha 2,8-sialique et leurs applications
EP2724723A1 (fr) 2012-10-25 2014-04-30 Universitätsklinikum Hamburg-Eppendorf Tégasérod pour un usage dans le traitement de lésions nerveuses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000054805A1 (fr) * 1999-03-15 2000-09-21 University Of Maryland, Baltimore COLLIGIN/HsP47 A LOCALISATION SUPERFICIELLE DANS LES CELLULES DES CARCINOMES
WO2002046408A2 (fr) * 2000-10-24 2002-06-13 Curagen Corporation Nouvelles proteines humaines, polynucleotides les codant et procedes d'utilisation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346512B1 (en) * 1996-07-12 2002-02-12 Mcgill University Compounds and methods for modulating cell adhesion
JP4150082B2 (ja) * 1996-08-27 2008-09-17 カイロン コーポレイション 独特の髄膜炎菌性ｂエピトープを規定するモノクローナル抗体およびワクチン組成物の調製におけるそれらの使用
EP1411061A1 (fr) * 2002-10-16 2004-04-21 Centre National De La Recherche Scientifique (Cnrs) Peptides mimetiques de l'acide poly-alpha 2,8-sialique et leurs applications

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000054805A1 (fr) * 1999-03-15 2000-09-21 University Of Maryland, Baltimore COLLIGIN/HsP47 A LOCALISATION SUPERFICIELLE DANS LES CELLULES DES CARCINOMES
WO2002046408A2 (fr) * 2000-10-24 2002-06-13 Curagen Corporation Nouvelles proteines humaines, polynucleotides les codant et procedes d'utilisation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HURPIN ET AL.: "Bactericidal activity of two IgG-2a murine monoclonal antibodies with distinct fine specificities for group B Neisseria meningitidis capsular polysaccharide.", HYBRIDOMA, vol. 11, no. 6, 1992, pages 667 - 687, XP009004404 *
SHIN ET AL.: "Monoclonal Antibodies Specific for Neisseria meningitidis Group B Polylsaccharide and Their Peptide Mimotopes", INFECTION AND IMMUNITY, vol. 69, 2001, pages 3335 - 3342, XP002228383 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103940985A (zh) * 2014-04-10 2014-07-23 首都医科大学 研究脑内源性神经干细胞迁移、增殖、分化的方法

Also Published As

Publication number Publication date
ATE490973T1 (de) 2010-12-15
DE60335278D1 (de) 2011-01-20
EP2295568A2 (fr) 2011-03-16
EP2295568A8 (fr) 2011-10-26
EP2295568A3 (fr) 2011-04-20
WO2004035609A3 (fr) 2004-08-26
CA2501994A1 (fr) 2004-04-29
EP1551867B1 (fr) 2010-12-08
DK1551867T3 (da) 2011-06-20
US8048858B2 (en) 2011-11-01
WO2004035609A2 (fr) 2004-04-29
JP2011016810A (ja) 2011-01-27
JP2006516186A (ja) 2006-06-29
US20090105131A1 (en) 2009-04-23
US20060122108A1 (en) 2006-06-08
ES2359810T3 (es) 2011-05-27
AU2003278501A8 (en) 2004-05-04
AU2003278501A1 (en) 2004-05-04
PT1551867E (pt) 2011-03-14
EP1551867A2 (fr) 2005-07-13
US7417025B2 (en) 2008-08-26

Similar Documents

Publication Publication Date Title
US6291247B1 (en) Methods of screening for factors that disrupt neurotrophin conformation and reduce neurotrophin biological activity
Okur et al. Promotion of neurite outgrowth by rationally designed NGF-β binding peptide nanofibers
Simon‐Haldi et al. Identification of a peptide mimic of the L2/HNK‐1 carbohydrate epitope
SK282267B6 (sk) Bombezínu antagonistický peptid, farmaceutický prostriedok s jeho obsahom a jeho použitie
US20150297693A1 (en) Peptide inhibitors for mediating stress responses
CN115260289A (zh) 一种炎症结肠靶向肽及其筛选方法
JPH07505908A (ja) Ｎｍｄａ受容体のアロステリックモジュレーター
US8048858B2 (en) Use of poly-α2,8-sialic acid mimetic peptides to modulate NCAM functions
AU5727499A (en) Ncam binding compounds
KR100968839B1 (ko) 포스파티딜세린과 특이적으로 결합하는 폴리펩티드 및 이의용도
WO2006105392A2 (fr) Peptides de ciblage de neurones
JP2004515534A (ja) 生存を促進するｎｃａｍ結合化合物およびｎｃａｍリガンド結合化合物
JP5967448B2 (ja) ２型ｔｎｆ受容体の発現を誘導する合成ペプチド及びその利用
KR102006890B1 (ko) 췌장 소도 세포 표적 펩타이드 및 이의 용도
EP1000142A1 (fr) Procede de criblage de bibliotheques de bacteriophages
EP1507797A2 (fr) Inhibiteurs de proteines de la famille rho-gef
CN103539840A (zh) 表皮生长因子受体模拟表位肽及其应用
CN101578368A (zh) 包括通过调节先天免疫治疗和预防感染在内的治疗和预防免疫相关疾病的新型肽
Nawaz et al. Biological impact of iberdomide in patients with active systemic lupus erythematosus Menu

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040217